Sponsor Overview
Explore verified public information about Leap Therapeutics, Inc.'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 2 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“Leap Therapeutics operates two types of access programs, as described in this document: 1. Post-Trial Access – Continued treatment for patients successfully completing one of our clinical studies 2. Early Access – The provision of access to a Leap Therapeutics IMP for patients suffering from a disease that is not possible to be treated with currently available medicines, or patients are not able to participate in one of our clinical studies.”
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 1 supporting sources.
Conditions: Esophageal Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, GastroEsophageal Cancer, Squamous Cell Carcinoma, Gastric Adenocarcinoma, Endometrial Cancer, Uterine Cancer, Ovarian Cancer, Carcinosarcoma, Gastric Cancer
Reagan-Udall Foundation Insights
Disease/Category-Specific EA Policies/Criteria https://www.leaptx.com/for-patients
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.